Abstract

Background

The use of extracorporeal membrane oxygenation (ECMO) in cases of near-fatal asthma (NFA) has increased, but the benefits and potential complications of this therapy have yet to be fully investigated.

Methods

Cases were extracted from the Extracorporeal Life Support Organization Registry between March 1992 and March 2016. All patients with a diagnosis of asthma (according to the International Classification of Diseases 9th edition), who also received ECMO, were extracted. Exclusion criteria included patients who underwent multiple courses of ECMO; those who received ECMO for cardiopulmonary resuscitation or cardiac dysfunction; and those with another primary diagnosis, such as sepsis. We analyzed survival to hospital discharge, complications, and clinical factors associated with in-hospital mortality, in patients with severe life-threatening NFA requiring ECMO support.

Conclusions

ECMO can provide adequate gas exchange and prevent lung injury induced by mechanical ventilation, and may be an effective bridging strategy to avoid aggressive ventilation in refractory NFA. However, careful management is required to avoid complications.

Keywords

Background

Near-fatal asthma (NFA) is a life-threatening condition caused by acute respiratory failure, and is the most severe clinical presentation of asthma [1, 2]. Although there are no specific diagnostic criteria for NFA, it is characterized by cardiorespiratory arrest, hypercapnia, acidemia, and the need for intubation and mechanical ventilation [3]. NFA can progress to fatal asthma, and the mortality rate varies widely across countries. In 2015, there were 3615 deaths from asthma in the USA [4]. Despite recent advances in treatment, the mortality rate for asthma has not changed significantly. It may be that much of the current asthma mortality is due to unpredictable deaths in the context of NFA [5]. Globally, nearly 30% of NFA cases result in significant morbidity and mortality [4–10]. Traditionally, protective mechanical ventilation with rescue therapy, including neuromuscular blockade, has been the mainstay treatment for NFA. However, technical advances in extracorporeal membrane oxygenation (ECMO) have made it a promising alternative therapy in the treatment of life-threatening NFA [11–13].

ECMO can provide adequate gas exchange during acute respiratory failure, and can help prevent lung injury induced by aggressive mechanical ventilation. Using data from the multicenter Extracorporeal Life Support Organization (ELSO) Registry, a previous study showed that ECMO support improved survival in patients with status asthmaticus to a greater degree than in other respiratory conditions [11]. However, this study included a small number of cases. The low incidence of NFA may preclude large-scale, prospective randomized trials on the effectiveness of ECMO in this context. Nevertheless, an increasing number of reports suggest ECMO may be an effective rescue therapy for NFA [12, 13].

Despite the potential benefits of ECMO in NFA, concerns remain about complications. In general, complications are the primary factor limiting the effectiveness of ECMO in many diseases. Evidence supporting ECMO use in NFA is lacking, and questions about the safety and effectiveness of ECMO in NFA remain unanswered. In this study, we reviewed data from the ELSO Registry collected between March 1992 and March 2016. Our aim was to investigate survival to hospital discharge, complications, and clinical factors associated with in-hospital mortality, in patients with severe life-threatening NFA requiring ECMO support.

Methods

The ELSO Registry is a worldwide voluntary registry. Currently, data are reported from 350 international ECMO centers. Data are collected using a standardized form, and include patient demographics, pre-ECMO ventilator settings, pre-ECMO arterial blood gas analysis (ABGA), post-ECMO ventilator settings, ECMO complications, and survival to hospital discharge [14]. Driving pressure (ΔP) was calculated as ventilator-measured plateau pressure minus applied positive end-expiratory pressure (PEEP). Diagnostic information is reported using the International Classification of Diseases 9th edition (ICD-9) codes, and indications for ECMO application are categorized as cardiac, respiratory, or extracorporeal cardiopulmonary resuscitation (ECPR). The study was approved by the Institutional Review Board (IRB) of Pusan National University Yangsan Hospital (IRB no.05-2017-066). Informed consent was not sought due to the retrospective nature of the study.

Patient cohorts

Between March 1992 and March 2016, 24,147 adults aged over 18 years were registered in the ELSO database. All cases of ECMO use in the context of an ICD-9 diagnosis of asthma were extracted (N = 568). Patients receiving ECMO support for ECPR or cardiac dysfunction were excluded according to the support type (ECPR, cardiac, or respiratory), and multiple ECMO courses were excluded. To discriminate between asthma and other non-asthmatic respiratory ECMO cases, patients with other primary diagnoses were also excluded. For example, a patient with asthma who received ECMO for sepsis was excluded, as sepsis was the primary indication for therapy. In total, 272 patients were included in the NFA group (Fig. 1).

Fig. 1

Patient inclusion in the study. In total, 272 patients were included in the study. ECPR, extracorporeal cardiopulmonary resuscitation

Statistical analysis

Data were reported as mean values with standard deviations for normally distributed data, or frequencies with proportions for categorical data. We compared the demographics, pre-ECMO and post-ECMO values, and ECMO complications between survivors and non-survivors among patients with NFA. Student’s t test was used for continuous data and the Fisher’s exact or Pearson’s chi-square test was used for categorical data. Pre-ECMO and post-ECMO ventilator settings were compared using the paired t test.

Binary logistic regression analysis was used to identify predictors of in-hospital mortality. Significant and borderline values (≤0.05) were entered into stepwise backward multivariable logistic regression, including age as the continuous covariate, to estimate factors associated with mortality prior to hospital discharge. Two-way interaction terms were tested between the remaining significant variables. A p value <0.05 was considered significant. Age, pre-ECMO ventilator settings, pre-ECMO ABGA, post-ECMO ventilator settings, and ECMO complications were used as predictors.

Results

Baseline patient characteristics

Among the 24,147 adult patients in the ELSO registry, 568 patients had a diagnosis of asthma according to the ICD-9 code (2.4%). Of these, 272 patients met the criteria for inclusion in the study. The use of ECMO for NFA in adults has been growing rapidly since 1992 (Additional file 1). The baseline clinical characteristics of the patients are presented in Table 1. Mean age was 36.2 years (range, 18–83 years). Mean body weight was 88.0 kg and. 39.7% of the patients were men. Pre-ECMO ABGA showed hypercapnic acidosis with mean pH of 7.1, mean partial pressure of carbon dioxide of 80.5 mmHg, and mean partial pressure of arterial oxygen/mean fraction of inspired oxygen (FiO2) ratio of 153.7. The mean values of the ventilator settings were relatively high. Prior to ECMO initiation, the mean peak inspiratory pressure (PIP) was 38.2 cmH2O; mean airway pressure was 21.4 cmH2O; mean PEEP was 8.3 cmH2O; mean FiO2 was 81.2%; and mean driving pressure was 29.2 cmH2O.

Complications and outcomes during extracorporeal membrane oxygenation support

Variables

Total

N = 272

Survivor

N = 227

Non-survivor

N = 45

p

Mechanical

67 (24.6)

48 (21.1)

19 (42.2)

0.003

Oxygenator failure

14 (5.1)

7 (3.1)

7 (15.6)

0.001

Clots: oxygenator

31 (11.4)

26 (11.5)

5 (11.1)

0.947

Clots: other

10 (3.7)

6 (2.6)

4 (8.9)

0.042

Cannula problems

12 (4.4)

9 (4.0)

3 (6.7)

0.304

Total bleeding

77 (28.3)

52 (22.9)

25 (55.6)

< 0.001

GI hemorrhage

7 (2.6)

5 (2.2)

2 (4.4)

0.386

Cannulation site bleeding

37 (13.6)

25 (11.0)

12 (26.7)

0.005

Surgical site bleeding

23 (8.5)

16 (7.0)

7 (15.6)

0.061

Pulmonary hemorrhage

14 (5.1)

7 (3.1)

7 (15.6)

0.001

Neurologic

13 (4.8)

9 (4.0)

4 (8.9)

0.157

Brain death

6 (2.2)

3 (1.3)

3 (6.7)

0.026

Seizures

7 (2.6)

6 (2.6)

1 (2.2)

0.871

Cerebral infarction

8 (2.9)

2 (0.9)

6 (13.3)

< 0.001

Cerebral hemorrhage

12 (4.4)

7 (3.1)

5 (11.1)

0.017

Renal

73 (26.8)

55 (24.2)

18 (40)

0.029

Dialysis required

54 (19.9)

39 (17.2)

15 (33.3)

0.013

Cardiovascular

71 (26.1)

57 (25.1)

14 (31.1)

0.402

Infection culture proven

45 (16.5)

34 (15.0)

11 (24.4)

0.118

Pneumothorax requiring treatment

14 (5.1)

12 (5.3)

2 (4.4)

0.815

Metabolic

61 (22.4)

50 (22.0)

11 (24.4)

0.722

Limb ischemia

7 (2.6)

5 (2.2)

2 (4.4)

0.386

Total complication

177 (65.1)

138 (60.8)

39 (86.7)

0.001

Weaning success

234 (86.7)

227 (100)

7 (15.6)

< 0.001

Values are shown as number (%) or mean ± SD

ECMO extracorporeal membrane oxygenation, GI gastrointestinal

Overall, the rate of weaning success was 86.7% (234/272) and the rate of survival to discharge was 83.5% (227/272). Among non-survivors, 15.6% (7/45) died after ECMO weaning. The most common reason for death was organ failure (37.8%, 17/45; Additional file 2).

Discussion

To our knowledge, this is the largest study of patients who have received ECMO for NFA refractory to mechanical ventilation. In this study, ventilator settings significantly improved after ECMO initiation to allow protective ventilation. Overall survival to hospital discharge was 83.5%, which was favorable compared to the ECMO outcome of other types of respiratory failure. Otherwise, ECMO complication was still common, even though it was mostly not serious. The total complication rate was 65.1%, with hemorrhagic complications being the most common (28.3%). Although bleeding was associated with increased in-hospital mortality, fatal bleeding only occurred in 1.5% of cases and most other complications were not fatal. Therefore, ECMO may be an effective treatment to prevent ventilator-induced lung injury in NFA refractory to mechanical ventilation. In addition, careful monitoring is required to detect and manage complications early and reduce their impact.

The mortality rate of patients with asthma is decreasing, but remains significant [9, 10]. While mechanical ventilation is a potentially life-saving intervention, a large proportion of the morbidity and mortality seen in patients with asthma may be related to the mechanical ventilation itself rather than to disease progression [15–18]. Regardless of the mode of ventilation selected, mechanical ventilation in NFA should aim to avoid barotrauma, minimize dynamic hyperinflation, maintain adequate oxygenation, and allow some degree of permissive hypercapnia until bronchodilators and steroids improve airflow [19]. However, this strategy may be impossible in patients with severe NFA. A new therapeutic approach is needed to reduce lung damage in patients with severe NFA requiring treatment with maximal ventilator settings.

Traditionally, overt hypercapnic acidosis in patients with acute severe asthma is significantly associated with higher rates of invasive ventilation; this leads to longer hospital stays, more complications, and a higher mortality rate [20]. In general, it is recommended that a moderate degree of hypercarbia and respiratory acidosis be tolerated in NFA, and that airway pressure be limited by using low respiratory rates and low tidal volumes [21]. Severe hypercapnea can recover rapidly once effective treatment has begun and hypoxemia is corrected. However, in severe cases with extreme airway obstruction, hypoxemia cannot be corrected despite maximal use of the mechanical ventilator. Death can occur as a result of asphyxia due to extreme airflow limitation and resulting hypoxia.

Despite limited data about physiologic and ventilator parameters, ventilator settings after ECMO initiation significantly improved, particularly driving pressure and PIP. Driving pressure is considered to be a reasonable surrogate for transpulmonary pressure, and high transpulmonary pressure can cause lung injury or gross barotrauma [22, 23]. The high PIP seen before ECMO initiation may reflect possible dynamic hyperinflation, which can result in cardiovascular instability and barotrauma to the lung. Our results suggest that ECMO significantly improves gas exchange, despite a lower PIP and lower driving pressure. Therefore, the use of ECMO in NFA may reduce ventilator-induced lung injury and oxygen toxicity by allowing for decreased ventilator settings. In NFA, the time to restoration of airway patency and reactivity following conventional treatment is highly variable, and clinicians cannot predict when bronchospasm will resolve. ECMO should be considered before refractory NFA causes barotrauma and volutrauma. In particular, the ventilation/perfusion mismatch produced by increased airway resistance and airflow limitation may facilitate severe hypoxemia in NFA. Therefore, ECMO could be considered in patients with persistent signs of deterioration including severe hypoxemia, acidosis, and hemodynamic instability, despite maximal mechanical ventilation settings.

Complications were common, even though the rates were lower than in previous studies [9]. However, the total complication rate included all minor complications, even those unrelated to ECMO, such as hyperglycemia. Hemorrhage was the most common complication, particularly at the cannulation site. In general, cannulation-site hemorrhage is less lethal, and easier to manage than bleeding at other sites. Overall, there were few fatal complications and only four patients died due to hemorrhage (1.5%, Additional file 2). The hemorrhagic complications of ECMO support are known to significantly impact patient survival and quality of life [24]. In this study, hemorrhage was independently associated with increased in-hospital mortality. Maintaining the balance between hemostasis and anticoagulation is difficult, and it remains a major challenge during ECMO [25, 26]. Unfortunately, the ELSO Registry did not include information about anticoagulation management. Clinicians should assess patient risk factors for ECMO-related hemorrhage, and actively take steps to correct them. In selected cases, termination of ECMO support may be required to prevent hemorrhage. Fortunately, ECMO stabilzes platelet function and the risk of hemorrhage is low in the early period of administration [27]. Furthermore, there is a recent trend toward conservative anticoagulation strategies to decrease complications due to hemorrhage [24, 28]. Considering the reversibility of airflow obstruction in asthma, ECMO can be safely used in these patients for a short period of time. However, careful management is required to balance the risks and benefits. The need for ECMO support should be reassessed when hemorrhagic complications are likely to be fatal.

This study had several limitations. First, we analyzed data voluntarily submitted by various international centers; these data may be susceptible to information bias, reporting bias, and uncontrolled confounding factors. Second, we defined patients with NFA as those with a primary ICD-9 diagnosis code of asthma. This may limit the applicability of these results to certain cases. Third, the ABGA values following ECMO initiation were not always present in this dataset, and as such their improvement could not be assessed as a secondary outcome. Furthermore, many of the baseline ventilator settings in this dataset did not adhere to the generally recommended criteria [21]. In these cases, refractory airway obstruction and unstable blood gas profiles might be related to suboptimal ventilator strategies. While this registry may not be representative of all cases, the strength of this study was that cases were extracted from a relatively large, international dataset. The data are also contemporary and reflect the current status of ECMO use in NFA. A further strength of the study was that the detailed complication profiles are present in the ELSO data. Because asthma is a reversible disease, it is important to know the complications associated with therapeutic interventions. This analysis provides important and current information to guide a rapid increase in the use of ECMO in NFA.

Conclusions

The management of NFA remains a significant problem in critical care. Mechanical ventilation of patients with NFA is challenging, and high ventilator settings may cause lung injury and hemodynamic instability secondary to barotrauma and dynamic hyperinflation. As NFA is ultimately reversible, clinicians should actively consider ECMO to both provide adequate gas exchange and prevent lung injury. In this study, ECMO provided full respiratory support in patients with NFA, and its use resulted in acceptable survival to hospital discharge. However, ECMO-related complications are common. To encourage the use of ECMO as a rescue therapy, understanding and reducing ECMO-related complications should be a priority. The use of ECMO to reduce ventilator-induced lung injury may reduce overall NFA mortality worldwide. Further clinical research into the use of ECMO in this context is needed.

Abbreviations

ABGA:

Arterial blood gas analysis

ECMO:

Extracorporeal membrane oxygenation

ECPR:

Extracorporeal cardiopulmonary resuscitation

ELSO:

Extracorporeal Life Support Organization

FiO2
:

Fraction of inspired oxygen

ICD-9:

International Classification of Diseases 9th edition

NFA:

Near-fatal asthma

PEEP:

Positive end-expiratory pressure

PIP:

Peak inspiratory pressure

VV:

Venovenous

Declarations

Acknowledgements

We truly appreciate Peter Rycus, MPH. who had contributed in the acquisition of data from Extracorporeal Life Support Organization (ELSO) database.

Funding

No funding to declare.

Availability of data and materials

Not applicable.

Authors’ contributions

Study concept and design: YHJ, CWH, KDH. Acquisition of data: PR. Analysis and interpretation of data: YHJ, CWH. Writing of the manuscript: YHJ, CWH. Critical revision of the manuscript: JD, CWH, KYS. Support for data collection: KDH. Approval of final manuscript and agreement of submission: all authors.

Authors’ information

Not applicable.

Ethics approval and consent to participate

The study was approved by the Institutional Review Board of Pusan National University Yangsan Hospital (IRB no.05-2017-066). Informed consent was not sought due to the retrospective nature of the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.